Synopsis of recent research by authors named "Xing-sheng Hu"
- Xing-Sheng Hu's recent research primarily focuses on advancements in treatment options and outcomes for non-small cell lung cancer (NSCLC), especially concerning the efficacy of dacomitinib and afatinib in patients with uncommon mutations in the epidermal growth factor receptor (EGFR) gene.
- His studies, including the AFANDA Study, compared the effectiveness of these treatments, revealing critical insights into safety, resistance mechanisms, and the patterns of progression in NSCLC.
- Additionally, Hu has explored the predictive value of circulating tumor cells (CTCs) in small cell lung cancer (SCLC) and has examined prognostic factors for extensive-stage SCLC, contributing to a broader understanding of lung cancer's clinical management.
